Literature DB >> 15579282

Cerebrospinal fluid markers that predict SIV CNS disease.

J L Mankowski1, S E Queen, J E Clements, M C Zink.   

Abstract

Predictive cerebrospinal fluid markers would provide valuable tools for tracking the development and progression of HIV CNS disease. In this study, expression of IL-6, MCP-1, and viral RNA in cerebrospinal fluid collected from SIV-inoculated macaques during acute, asymptomatic, and terminal stages of infection was quantitated to determine whether one or several of these parameters paralleled the severity of SIV encephalitis. Animals that developed moderate to severe SIV encephalitis had significantly elevated levels of CSF IL-6, MCP-1, and SIV RNA during asymptomatic infection and persisting through terminal disease as compared to animals developing mild or no CNS disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579282     DOI: 10.1016/j.jneuroim.2004.08.031

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  58 in total

1.  PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation.

Authors:  Toni K Roberts; Eliseo A Eugenin; Susan Morgello; Janice E Clements; M Christine Zink; Joan W Berman
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages.

Authors:  Rajnish S Dave
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03

3.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

4.  Microglia activation by SIV-infected macrophages: alterations in morphology and cytokine secretion.

Authors:  Nicole A Renner; Hope A Sansing; Lisa A Morici; Fiona M Inglis; Andrew A Lackner; Andrew G MacLean
Journal:  J Neurovirol       Date:  2012-04-26       Impact factor: 2.643

5.  Host and virus strain dependence in activation of human macrophages by human immunodeficiency virus type 1.

Authors:  Katarzyna Kazmierczak; Mary Jane Potash
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Neuroinvasion of fluorescein-positive monocytes in acute simian immunodeficiency virus infection.

Authors:  Candice C Clay; Denise S Rodrigues; Yan S Ho; Beth A Fallert; Kim Janatpour; Todd A Reinhart; Ursula Esser
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

8.  Cognitive impairment following high fat diet consumption is associated with brain inflammation.

Authors:  Paul J Pistell; Christopher D Morrison; Sunita Gupta; Alecia G Knight; Jeffrey N Keller; Donald K Ingram; Annadora J Bruce-Keller
Journal:  J Neuroimmunol       Date:  2009-12-08       Impact factor: 3.478

9.  Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model.

Authors:  Gigi J Ebenezer; Victoria A Laast; Brandon Dearman; Peter Hauer; Patrick M Tarwater; Robert J Adams; M Christine Zink; Justin C McArthur; Joseph L Mankowski
Journal:  J Comp Neurol       Date:  2009-05-20       Impact factor: 3.215

10.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.